

YUVIWEL can help make the difference

Discover the first and only FDA-approved,
once-weekly treatment for children
with achondroplasia.

Brynlyn, 11 years old
Taking YUVIWEL as part of
a clinical trial since age 7

In a 1-year study, children 2 to 12 years old with achondroplasia who received YUVIWEL grew faster than those who received placebo.

USE AND IMPORTANT SAFETY INFORMATION

What is YUVIWEL?

YUVIWEL is a prescription medicine used to increase linear growth in children 2 years and older with achondroplasia with open growth plates (epiphyses).

YUVIWEL is approved under accelerated approval based on an improvement in annualized growth velocity. Continued approval may be contingent upon verification and description of clinical benefit in confirmatory trials.

IMPORTANT SAFETY INFORMATION

What are the possible side effects of YUVIWEL?

YUVIWEL may cause serious side effects, including risk of low blood pressure. If your child experiences a decrease in blood pressure or symptoms of low blood pressure (dizziness, feeling tired, and/or nausea) while being treated with YUVIWEL, call your child's healthcare provider.

Please see Important Safety Information throughout and the full [Prescribing Information](#) and [Patient Information](#) for YUVIWEL.



There are things that seem small but are big in life. She can reach the milk, wash her own hair, and ride a bike without adjustments. The growth has helped her.

- Brandi, Brynlyn's mom

Brynlyn, 11 years old
Taking YUVIWEL as part of a clinical trial since age 7

IMPORTANT SAFETY INFORMATION (cont'd)

What are the possible side effects of YUVIWEL? (cont'd)

The most common side effects of YUVIWEL include injection site reactions (redness, itching, skin discoloration, bleeding, swelling, bruising, pain, and blistering).

Please see Important Safety Information throughout and the full Prescribing Information and Patient Information for YUVIWEL.


yuviwel
navepegritide
for injection 1.3 • 2.8 • 5.5 mg

How YUVIWEL works

Achondroplasia is a rare genetic condition that affects how bones grow and develop. It is caused by a change in a gene called FGFR3.


Typical bone growth happens when 2 factors are in balance:



In achondroplasia, **FGFR3 is overactive and slows bone growth too much.**



YUVIWEL works with the body's natural CNP to promote bone growth.



Porter, 4 years old
Taking YUVIWEL as
part of a clinical
trial since age 2

“We thought that YUVIWEL would be the best opportunity for us because it was a once-weekly injection.”

- Lauren, Porter's mom

YUVIWEL provides a steady level of CNP (the active ingredient that promotes growth) throughout the week.

IMPORTANT SAFETY INFORMATION (cont'd)

Before you give YUVIWEL to your child, tell the healthcare provider about all of your child's medical conditions, including if they:

- have kidney problems
- are pregnant or plan to become pregnant. It is not known if YUVIWEL will harm the unborn baby
- are breastfeeding or plan to breastfeed. It is not known if YUVIWEL passes into breast milk

Please see Important Safety Information throughout and the full Prescribing Information and Patient Information for YUVIWEL.

yuviwel
navepegritide
for injection 1.3 • 2.8 • 5.5 mg

YUVIWEL can be part of a treatment plan designed to help your child grow

Your child can take once-weekly YUVIWEL from age 2 until their growth plates close



- Growth plates are the parts of a child's bones that make growth possible.
- “Open” growth plates mean that growth is still possible
 - “Closed” growth plates mean that no more growth is possible. This happens at the end of puberty

YUVIWEL works in the limited time that growth plates are open.

IMPORTANT SAFETY INFORMATION (cont'd)

Tell the healthcare provider about all the medicines your child takes, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

These are not all of the possible side effects of YUVIWEL. Call your doctor for medical advice about side effects. **You are encouraged to report side effects to FDA at 1-800-FDA-1088 or at www.fda.gov/medwatch.** You may also report side effects to Ascendis Pharma at 1-844-442-7236.

Please see Important Safety Information throughout and the full Prescribing Information and Patient Information for YUVIWEL.



Porter, 4 years old
Taking YUVIWEL as part of a clinical trial since age 2.
Others are not actual patients.



Explore more about YUVIWEL and how treatment may benefit your child.




The YUVIWEL difference

In a 1-year study of children with achondroplasia, on average:

- Children getting YUVIWEL grew faster than those getting placebo (an injection with no medicine), regardless of age
- The YUVIWEL group grew 0.6 inches (1.5 centimeters) more per year than the placebo group
 - Children under 5 years of age grew 0.4 inches more per year, while children 5 and older grew 0.7 inches more per year
- In an ongoing study, children who continued getting YUVIWEL over 2 years maintained their faster rate of growth throughout treatment

Growth per year with YUVIWEL vs placebo



The YUVIWEL study was made up of 84 children aged 2 to 12. The study measured how many inches a child grew in a year (at the end of 52 weeks). This measurement is called **annualized growth velocity (AGV)**.



Colton, 8 years old
Taking YUVIWEL as part of a clinical trial since age 2

IMPORTANT SAFETY INFORMATION (cont'd)

What is YUVIWEL?

YUVIWEL is a prescription medicine used to increase linear growth in children 2 years and older with achondroplasia with open growth plates (epiphyses).

YUVIWEL is approved under accelerated approval based on an improvement in annualized growth velocity. Continued approval may be contingent upon verification and description of clinical benefit in confirmatory trials.

YUVIWEL is approved based on improvement in AGV over 1 year.

Ongoing studies are in progress to assess the efficacy and safety of YUVIWEL over a longer period of time. In addition, there is continued monitoring of additional study endpoints of leg bowing, body proportionality, and physical functioning.

Please see Important Safety Information throughout and the full Prescribing Information and Patient Information for YUVIWEL.



YUVIWEL has an established safety profile



The most common side effects were vomiting, injection site reactions, pain in the arms and legs, and nausea. Injection site reactions included redness, itching, skin discoloration, bleeding, swelling, bruising, pain, and blistering.



3% of children treated with YUVIWEL saw an increase in hair growth either near the injection site or on the limbs, back, and shoulders, compared with 0% of children who received placebo. Rotating the site of injection with each dose can reduce this risk.



- In the YUVIWEL study, no one stopped treatment because of side effects
- All injection site reactions were mild. On average, children experienced less than 1 injection site reaction per 2 years on YUVIWEL



Colton, 8 years old
Taking YUVIWEL as part of a clinical trial since age 2

Please see Important Safety Information throughout and the full Prescribing Information and Patient Information for YUVIWEL.


navepegritide[®]
for injection 1.3 • 2.8 • 5.5 mg

Once-weekly YUVIWEL fits into a busy schedule



YUVIWEL is a once-weekly injection. It can be given at any time of day that fits your family routine best. There's no need to plan around meals, snacks, or bedtimes.



Once weekly means **313 injection-free days per year.**



While it's best for YUVIWEL to be given on the same day each week, sometimes life happens and plans change. **So, it's good to know that the dosing day can be adjusted to 2 days before or 2 days after the planned dosing day if needed.** Resume once-weekly dosing for the next dose at the usual dosing day.

Missed doses:

- If more than 2 days have passed from the scheduled dosing day, skip the missed dose and give YUVIWEL on the next regularly scheduled day
- There should be at least 5 days between doses

IMPORTANT SAFETY INFORMATION (cont'd)

What are the possible side effects of YUVIWEL?

YUVIWEL may cause serious side effects, including risk of low blood pressure. If your child experiences a decrease in blood pressure or symptoms of low blood pressure (dizziness, feeling tired, and/or nausea) while being treated with YUVIWEL, call your child's healthcare provider.



Brynlyn, 11 years old
Taking YUVIWEL as
part of a clinical
trial since age 7



Switch without missing a treatment day: Your child can start once-weekly YUVIWEL the day after their last dose of their daily CNP treatment.



YUVIWEL is easy to store. Unmixed YUVIWEL can be kept in the fridge or at room temperature.



Ascendis supports you with free at-home injection training, so you can learn how to give YUVIWEL to your child safely and properly.



Once-weekly dosing reduces space, storage, and supplies needed for injections. Each carton of YUVIWEL contains 4 small kits with everything you need for 4 weekly injections.



Watch the Instructions for Use video before giving YUVIWEL.

Please see Important Safety Information throughout and the full Prescribing Information and Patient Information for YUVIWEL.



Personalized support every step of the way

The Ascendis Signature Access Program (A•S•A•P) provides ongoing assistance throughout your treatment journey.*



*A•S•A•P helps provide patient support services to eligible patients who have been prescribed YUVIWEL for its approved indication.

Through A•S•A•P, a Patient Access Liaison (PAL) can answer questions and provide support along the way:



Helps you understand your insurance coverage, benefits, and financial support options



Provides injection training support



Provides information about achondroplasia and how YUVIWEL can fit into your child's treatment plan

Financial support

Eligible patients with commercial health insurance may pay as little as \$0 per month for YUVIWEL[†]

If you do not have insurance or are underinsured, you may qualify for treatment at \$0 through the Ascendis Patient Assistance Program (PAP)[‡]

[†]Eligibility: Federal and state healthcare beneficiaries are ineligible (participants in programs such as Medicaid, Medicare, Medigap, VA, DOD, or TRICARE). Offer not valid for cash-paying patients. Terms and conditions apply. For full terms and conditions and eligibility criteria, visit yuviwel.com/pdf/copay-terms.pdf.

[‡]For full terms and conditions, visit yuviwel.com/pdf/pap-terms.pdf.



Connect with a PAL now.

Helpful resources for children with achondroplasia and their families

Advocacy groups like these can help connect families to resources and help them feel like part of a community.



Improving the quality of medical care for those living with dwarfism by supporting research.



Founded in 1957, Little People of America (LPA) is the largest and longest-standing organization supporting people with dwarfism. Through a national network of districts, LPA provides support, education, and advocacy that reflect and celebrate the identities and lived experiences of people with short stature.



Dedicated to empowering and supporting individuals with skeletal dysplasia and their families.



Raising awareness of transformative research on achondroplasia and other skeletal dysplasias by supporting a global community and network of patients, parents, and caregivers seeking information.

Advocacy groups are provided for informational purposes.



Find a doctor near you with experience in achondroplasia.

Please see Important Safety Information throughout and the full Prescribing Information and Patient Information for YUVIWEL.



“

I hope parents know that they have options and that they don't have to be scared. Our children can be anything and do anything as long as they're supported.

- Amber, Colton's mom

”



Hear from caregivers like you as they share their experiences with once-weekly YUVIWEL.

Colton, 8 years old
Taking YUVIWEL as
part of a clinical
trial since age 2

IMPORTANT SAFETY INFORMATION (cont'd)

What are the possible side effects of YUVIWEL? (cont'd)

The most common side effects of YUVIWEL include injection site reactions (redness, itching, skin discoloration, bleeding, swelling, bruising, pain, and blistering).

Please see Important Safety Information throughout and the full Prescribing Information and Patient Information for YUVIWEL.


yuviwel
navepegritide[®]
for injection 1.3 • 2.8 • 5.5 mg

Discover once-weekly YUVIWEL



First and only once-weekly, FDA-approved treatment designed to help children with achondroplasia grow



Once weekly means 313 injection-free days per year



Can be given at any time of day that fits your family routine best



Established safety profile

Porter, 4 years old
Taking YUVIWEL
as part of a clinical
trial since age 2



**Connect with a Patient
Access Liaison now.**

USE AND IMPORTANT SAFETY INFORMATION

What is YUVIWEL?

YUVIWEL is a prescription medicine used to increase linear growth in children 2 years and older with achondroplasia with open growth plates (epiphyses).

YUVIWEL is approved under accelerated approval based on an improvement in annualized growth velocity. Continued approval may be contingent upon verification and description of clinical benefit in confirmatory trials.

IMPORTANT SAFETY INFORMATION

What are the possible side effects of YUVIWEL?

YUVIWEL may cause serious side effects, including risk of low blood pressure. If your child experiences a decrease in blood pressure or symptoms of low blood pressure (dizziness, feeling tired, and/or nausea) while being treated with YUVIWEL, call your child's healthcare provider.

Please see Important Safety Information throughout and the full Prescribing Information and Patient Information for YUVIWEL.



© July 2026 Ascendis Pharma Endocrinology, Inc. All rights reserved. YUVIWEL®, Ascendis Signature Access Program®, Ascendis®, the Ascendis Pharma logo and the company logo are registered trademarks owned by the Ascendis Pharma Group. US-COMMCNP-2600055 07/26



yuviwel
navepegritide
for injection 1.3 • 2.8 • 5.5 mg